France · Delayed Price · Currency is EUR Arkema Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw revenue and EBITDA decline amid weak demand in Europe and the U.S., but strong cash generation and cost savings exceeded targets. Outlook for 2026 is cautious, with slight EBITDA growth expected and continued focus on cost control and project ramp-up.
-
Q3 2025 saw sales down 8.6% year-on-year amid weak U.S. and European demand, but strong growth in Asia and targeted markets like batteries and fluorospecialties. Cost savings and disciplined capital allocation supported cash flow, with 2025 EBITDA guidance set at €1.25–1.3 billion.
-
Q2 2025 saw resilient margins and cash flow despite weak demand in Europe and the US, with Asia providing growth in high-performance polymers. 2025 EBITDA is guided at €1.3–1.4 billion, supported by cost savings and major project ramp-ups, while leverage remains stable.
-
Q1 2025 saw resilient specialty materials and strong growth in Asia, offset by weak demand in Europe and the U.S., with EBITDA down 6% year-over-year. Major projects and Dow adhesives integration are progressing, and full-year EBITDA is expected to match last year if macro conditions stabilize.
Fiscal Year 2024
-
2024 results were resilient with stable sales, 2% EBITDA growth, and a 16.1% margin. 2025 guidance targets further EBITDA growth to €1.53–1.67 billion, driven by major project ramp-ups, despite macro uncertainty and softness in Europe and the U.S.
-
Q3 2024 delivered 2.9% sales growth and 5.4% EBITDA increase, driven by specialty materials in Asia and the U.S., despite ongoing macroeconomic challenges. 2024 EBITDA is expected at the lower end of guidance, with major projects set to add €440 million EBITDA by 2028.
-
Q2 saw 5% volume growth and 8% EBITDA increase, with all segments contributing and adhesives leading. Annual EBITDA guidance is raised to €1.53–1.63 billion, despite macro headwinds and a €15 million flooding impact, as organic projects ramp up and M&A integration continues.